|Mr. Zeeshan Saeed||Founder & Exec. Co-Chairman||224.6k||N/A||1972|
|Mr. Anthony John Durkacz||Founder & Exec. Co-Chairman||N/A||N/A||1976|
|Dr. Raza Bokhari M.B.A., M.D., MBA||Chief Exec. Officer||1||N/A||1968|
|Dr. Sara May Ph.D.||Sr. VP||152.8k||N/A||N/A|
|Dr. Edward J. Brennan Jr., F.A.C.S., M.D., FACS||Chief Medical Officer||461.33k||N/A||N/A|
|Mr. Nathan Coyle CPA||CFO & Corp. Controller||N/A||N/A||N/A|
|Ms. Maryann Adesso||Corp. Sec.||N/A||N/A||N/A|
|Randell Mack||Pres of FSD BioSciences||N/A||N/A||N/A|
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.
FSD Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.